Evidence map›Paper›PMID 35193475›Full record

ArticleCancer biology & therapy2022

Personalized functional profiling using

Hichul Kim, Victoria El-Khoury, Nadine Schulte, Tianzuo Zhan, Johannes Betge, Loic Cousin, Emanuele Felli, Patrick Pessaux, Arnaud Ogier, Oliver Opitz and 3 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biology & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Neurooncology: 2023 update.Free neuropathology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Hichul KimEarly Discovery and Technology Development, Ksilink, Strasbourg, France.ORCID 0000-0003-2181-6642
Victoria El-KhouryPersonalized Therapy Discovery, Department of Oncology, Luxembourg Institute of Health, Dudelange, Luxembourg.ORCID 0000-0001-5234-8015
Nadine SchulteDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Mannheim, Germany.
Tianzuo ZhanDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Mannheim, Germany.ORCID 0000-0002-9346-3180
Johannes BetgeDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Mannheim, Germany.ORCID 0000-0001-9549-1866
Loic CousinEarly Discovery and Technology Development, Ksilink, Strasbourg, France.
Emanuele FelliDepartment of Visceral and Digestive Surgery, Nouvel Hopital Civil, University Hospital of Strasbourg, Strasbourg, France.ORCID 0000-0002-6510-1457
Patrick PessauxDepartment of Visceral and Digestive Surgery, Nouvel Hopital Civil, University Hospital of Strasbourg, Strasbourg, France.ORCID 0000-0001-5635-7437
Arnaud OgierEarly Discovery and Technology Development, Ksilink, Strasbourg, France.
Oliver OpitzCoordinating Unit for Digital Medicine Baden-Württemberg (Ktbw), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Bosung KuCentral R&D Center, Medical & Bio Decision (MBD), Suwon, Republic of Korea.ORCID 0000-0002-2388-6137
Matthias P EbertDepartment of Medicine II, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University Mannheim, Germany.
Yong-Jun KwonEarly Discovery and Technology Development, Ksilink, Strasbourg, France.ORCID 0000-0002-8697-4679
Heidelberg University · DELuxembourg Institute of Health · LUInserm · FRBio-Medical Science (South Korea) · KRGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung carcinoids are neuroendocrine tumors representing 1 to 2% of lung cancers. This study outlines the case of a patient with a metastatic lung atypical carcinoid who presented with a pleural effusion and progression of liver metastases after developing resistance to conventional treatments. Personalized functional profiling (PFP), i.e. drug screening, was performed in

Indexed as

Carcinoid TumorCarcinoma, NeuroendocrineLiver NeoplasmsLung NeoplasmsNeoplasms, Second PrimaryNeuroendocrine TumorsPleural EffusionHumansLungantiangiogenic therapydrug screeninglung carcinoidneuroendocrine tumorsPersonalized functional profilingpersonalized medicinepharmacotypingprecision medicinespheroids

Identifiers

PMID35193475
PMCPMC8890433
OpenAlexW4212898049

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.